1 192 123 ACETYLATED H4K16 BY MYST1 PROTECTS UROTSA CELLS FROM ARSENIC TOXICITY AND IS DECREASED FOLLOWING CHRONIC ARSENIC EXPOSURE. ARSENIC, A HUMAN CARCINOGEN THAT IS ASSOCIATED WITH AN INCREASED RISK OF BLADDER CANCER, IS COMMONLY FOUND IN DRINKING WATER. AN IMPORTANT MECHANISM BY WHICH ARSENIC IS THOUGHT TO BE CARCINOGENIC IS THROUGH THE INDUCTION OF EPIGENETIC CHANGES THAT LEAD TO ABERRANT GENE EXPRESSION. PREVIOUSLY, WE REPORTED THAT THE SAS2 GENE IS REQUIRED FOR OPTIMAL GROWTH OF YEAST IN THE PRESENCE OF ARSENITE (AS(III)). YEAST SAS2P IS ORTHOLOGOUS TO HUMAN MYST1, A HISTONE 4 LYSINE 16 (H4K16) ACETYLTRANSFERASE. HERE, WE SHOW THAT H4K16 ACETYLATION IS NECESSARY FOR THE RESISTANCE OF YEAST TO AS(III) THROUGH THE MODULATION OF CHROMATIN STATE. WE FURTHER EXPLORED THE ROLE OF MYST1 AND H4K16 ACETYLATION IN ARSENIC TOXICITY AND CARCINOGENESIS IN HUMAN BLADDER EPITHELIAL CELLS. THE EXPRESSION OF MYST1 WAS KNOCKED DOWN IN UROTSA CELLS, A MODEL OF BLADDER EPITHELIUM THAT HAS BEEN USED TO STUDY ARSENIC-INDUCED CARCINOGENESIS. SILENCING OF MYST1 REDUCED ACETYLATION OF H4K16 AND INDUCED SENSITIVITY TO AS(III) AND TO ITS MORE TOXIC METABOLITE MONOMETHYLARSONOUS ACID (MMA(III)) AT DOSES RELEVANT TO HIGH ENVIRONMENTAL HUMAN EXPOSURES. IN ADDITION, BOTH AS(III) AND MMA(III) TREATMENTS DECREASED GLOBAL H4K16 ACETYLATION LEVELS IN A DOSE- AND TIME-DEPENDENT MANNER. THIS INDICATES THAT ACETYLATED H4K16 IS REQUIRED FOR RESISTANCE TO ARSENIC AND THAT A REDUCTION IN ITS LEVELS AS A CONSEQUENCE OF ARSENIC EXPOSURE MAY CONTRIBUTE TO TOXICITY IN UROTSA CELLS. BASED ON THESE FINDINGS, WE PROPOSE A NOVEL ROLE FOR THE MYST1 GENE IN HUMAN SENSITIVITY TO ARSENIC. 2009 2 482 44 ARSENITE BINDS TO THE ZINC FINGER MOTIF OF TIP60 HISTONE ACETYLTRANSFERASE AND INDUCES ITS DEGRADATION VIA THE 26S PROTEASOME. ARSENIC IS A UBIQUITOUS ENVIRONMENTAL CONTAMINANT WITH WIDESPREAD PUBLIC HEALTH CONCERN. EPIDEMIOLOGICAL STUDIES HAVE REVEALED THAT CHRONIC HUMAN EXPOSURE TO ARSENIC IN DRINKING WATER IS ASSOCIATED WITH THE PREVALENCE OF SKIN, LUNG, AND BLADDER CANCERS. ABERRANT HISTONE MODIFICATIONS (E.G., METHYLATION, ACETYLATION, AND UBIQUITINATION) WERE PREVIOUSLY FOUND TO BE ACCOMPANIED BY ARSENIC EXPOSURE; THUS, PERTURBATION OF EPIGENETIC PATHWAYS IS THOUGHT TO CONTRIBUTE TO ARSENIC CARCINOGENESIS. ARSENITE IS KNOWN TO INTERACT WITH ZINC FINGER MOTIFS OF PROTEINS, AND ZINC FINGER MOTIF IS PRESENT IN AND INDISPENSABLE FOR THE ENZYMATIC ACTIVITIES OF CRUCIAL HISTONE-MODIFYING ENZYMES ESPECIALLY THE MYST FAMILY OF HISTONE ACETYLTRANSFERASES (E.G., TIP60). HENCE, WE REASONED THAT TRIVALENT ARSENIC MAY TARGET THE ZINC FINGER MOTIF OF THESE ENZYMES, DISTURB THEIR ENZYMATIC ACTIVITIES, AND ALTER HISTONE ACETYLATION. HEREIN, WE FOUND THAT AS(3+) COULD BIND DIRECTLY TO THE ZINC-FINGER MOTIF OF TIP60 IN VITRO AND IN CELLS. IN ADDITION, EXPOSURE TO AS(3+) COULD LEAD TO A DOSE-DEPENDENT DECREASE IN TIP60 PROTEIN LEVEL VIA THE UBIQUITIN-PROTEASOME PATHWAY. THUS, THE RESULTS FROM THE PRESENT STUDY REVEALED, FOR THE FIRST TIME, THAT ARSENITE MAY TARGET CYSTEINE RESIDUES IN THE ZINC-FINGER MOTIF OF THE TIP60 HISTONE ACETYLTRANSFERASE, THEREBY ALTERING THE H4K16AC HISTONE EPIGENETIC MARK. OUR RESULTS ALSO SHED SOME NEW LIGHT ON THE MECHANISMS UNDERLYING THE ARSENIC-INDUCED EPIGENOTOXICITY AND CARCINOGENESIS IN HUMANS. 2017 3 476 40 ARSENIC INDUCES FIBROGENIC CHANGES IN HUMAN KIDNEY EPITHELIAL CELLS POTENTIALLY THROUGH EPIGENETIC ALTERATIONS IN DNA METHYLATION. ARSENIC CONTAMINATION IS A SIGNIFICANT PUBLIC HEALTH ISSUE, AND KIDNEY IS ONE OF THE TARGET ORGAN FOR ARSENIC-INDUCED ADVERSE EFFECTS. RENAL FIBROSIS IS A WELL-KNOWN PATHOLOGICAL STAGE FREQUENTLY OBSERVED IN PROGRESSIVE CHRONIC KIDNEY DISEASE (CKD). EPIDEMIOLOGICAL STUDIES IMPLICATE ARSENIC EXPOSURE TO CKD, BUT THE ROLE OF ARSENIC IN KIDNEY FIBROSIS AND THE UNDERLYING MECHANISM IS STILL UNCLEAR. IT IS IN THIS CONTEXT THAT THE CURRENT STUDY EVALUATED THE EFFECTS OF LONG-TERM ARSENIC EXPOSURE ON THE CELLULAR RESPONSE IN MORPHOLOGY, AND MARKER GENES EXPRESSION WITH RESPECT TO FIBROSIS USING HUMAN KIDNEY 2 (HK-2) EPITHELIAL CELLS. RESULTS OF THIS STUDY REVEALED THAT IN ADDITION TO INCREASED GROWTH, HK-2 CELLS UNDERWENT PHENOTYPIC, BIOCHEMICAL AND MOLECULAR CHANGES INDICATIVE OF EPITHELIAL-MESENCHYMAL TRANSITION (EMT) IN RESPONSE TO THE EXPOSURE TO ARSENIC. MOST IMPORTANTLY, THE ARSENIC-EXPOSED CELLS ACQUIRED THE PATHOGENIC FEATURES OF FIBROSIS AS SUPPORTED BY INCREASED EXPRESSION OF MARKERS FOR FIBROSIS, SUCH AS COLLAGEN I, FIBRONECTIN, TRANSFORMING GROWTH FACTOR BETA, AND ALPHA-SMOOTH MUSCLE ACTIN. UPREGULATION OF FIBROSIS ASSOCIATED SIGNALING MOLECULES SUCH AS TISSUE INHIBITOR OF METALLOPROTEINASES-3 AND MATRIX METALLOPROTEINASE-2 AS WELL AS ACTIVATION OF AKT WAS ALSO OBSERVED. ADDITIONALLY, THE EXPRESSION OF EPIGENETIC GENES (DNA METHYLTRANSFERASES 3A AND 3B; METHYL-CPG BINDING DOMAIN 4) WAS INCREASED IN ARSENIC-EXPOSED CELLS. TREATMENT WITH DNA METHYLATION INHIBITOR 5-AZA-2'-DC REVERSED THE EMT PROPERTIES AND RESTORED THE LEVEL OF PHOSPHO-AKT. TOGETHER, THESE DATA FOR THE FIRST TIME SUGGEST THAT LONG-TERM EXPOSURE TO ARSENIC CAN INCREASE THE RISK OF KIDNEY FIBROSIS. ADDITIONALLY, OUR DATA SUGGEST THAT THE ARSENIC-INDUCED FIBROTIC CHANGES ARE, AT LEAST IN PART, MEDIATED BY DNA METHYLATION AND THEREFORE POTENTIALLY CAN BE REVERSED BY EPIGENETIC THERAPEUTICS. 2019 4 473 34 ARSENIC AND URINARY BLADDER CELL PROLIFERATION. EPIDEMIOLOGIC STUDIES HAVE DEMONSTRATED THAT A CLOSE ASSOCIATION EXISTS BETWEEN THE ELEVATED LEVELS OF ARSENIC IN DRINKING WATER AND THE INCIDENCE OF CERTAIN CANCERS, INCLUDING TRANSITIONAL CELL CARCINOMAS OF THE URINARY BLADDER. WE HAVE EMPLOYED IN VITRO AND IN VIVO MODELS TO EXAMINE THE EFFECTS OF SODIUM ARSENITE ON THE URINARY BLADDER EPITHELIUM. MICE EXPOSED TO 0.01% SODIUM ARSENITE IN DRINKING WATER DEMONSTRATED HYPERPROLIFERATION OF THE BLADDER UROEPITHELIUM WITHIN 4 WEEKS AFTER INITIATING TREATMENT. THIS OCCURRED IN THE ABSENCE OF AMORPHOUS PRECIPITATES AND WAS ACCOMPANIED BY THE ACCUMULATION OF TRIVALENT ARSENITE (IAS(3+)), AND TO A LESSER EXTENT DIMETHYLARSENIC (DMA), ARSENATE (IAS(5+)), AND MONOMETHYLARSENIC (MMA) IN BLADDER TISSUE. IN CONTRAST TO THE BLADDER, URINARY SECRETION WAS PRIMARILY IN THE FORM OF DMA AND MMA. ARSENIC-INDUCED CELL PROLIFERATION IN THE BLADDER EPITHELIUM WAS CORRELATED WITH ACTIVATION OF THE MAP KINASE PATHWAY, LEADING TO EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) KINASE ACTIVITY, AP-1 ACTIVATION, AND EXPRESSION OF AP-1-ASSOCIATED GENES INVOLVED IN CELL PROLIFERATION. ACTIVATION OF THE MAP KINASE PATHWAY INVOLVED BOTH EPIDERMAL GROWTH FACTOR (EGF) RECEPTOR-DEPENDENT AND -INDEPENDENT EVENTS, THE LATTER INVOLVING SRC ACTIVATION. STUDIES SUMMARIZED IN THIS REVIEW SUGGEST THAT ARSENIC ACCUMULATES IN URINARY BLADDER EPITHELIUM CAUSING ACTIVATION OF SPECIFIC SIGNALING PATHWAYS THAT LEAD TO CHRONIC INCREASED CELL PROLIFERATION. THIS MAY PLAY A NON-EPIGENETIC ROLE IN CARCINOGENESIS BY INCREASING THE PROLIFERATION OF INITIATED CELLS OR INCREASING THE MUTATIONAL RATE. 2004 5 6562 34 TRANSIENT AND PERMANENT CHANGES IN DNA METHYLATION PATTERNS IN INORGANIC ARSENIC-MEDIATED EPITHELIAL-TO-MESENCHYMAL TRANSITION. CHRONIC LOW DOSE INORGANIC ARSENIC EXPOSURE CAUSES CELLS TO TAKE ON AN EPITHELIAL-TO-MESENCHYMAL PHENOTYPE, WHICH IS A CRUCIAL PROCESS IN CARCINOGENESIS. INORGANIC ARSENIC IS NOT A MUTAGEN AND THUS EPIGENETIC ALTERATIONS HAVE BEEN IMPLICATED IN THIS PROCESS. INDEED, DURING THE EPITHELIAL-TO-MESENCHYMAL TRANSITION, MORPHOLOGIC CHANGES TO CELLS CORRELATE WITH CHANGES IN CHROMATIN STRUCTURE AND GENE EXPRESSION, ULTIMATELY DRIVING THIS PROCESS. HOWEVER, STUDIES ON THE EFFECTS OF INORGANIC ARSENIC EXPOSURE/WITHDRAWAL ON THE EPITHELIAL-TO-MESENCHYMAL TRANSITION AND THE IMPACT OF EPIGENETIC ALTERATIONS IN THIS PROCESS ARE LIMITED. IN THIS STUDY WE USED HIGH-RESOLUTION MICROARRAY ANALYSIS TO MEASURE THE CHANGES IN DNA METHYLATION IN CELLS UNDERGOING INORGANIC ARSENIC-INDUCED EPITHELIAL-TO-MESENCHYMAL TRANSITION, AND ON THE REVERSAL OF THIS PROCESS, AFTER REMOVAL OF THE INORGANIC ARSENIC EXPOSURE. WE FOUND THAT CELLS EXPOSED TO CHRONIC, LOW-DOSE INORGANIC ARSENIC EXPOSURE SHOWED 30,530 SITES WERE DIFFERENTIALLY METHYLATED, AND WITH INORGANIC ARSENIC WITHDRAWAL SEVERAL DIFFERENTIAL METHYLATED SITES WERE REVERSED, ALBEIT NOT COMPLETELY. FURTHERMORE, THESE CHANGES IN DNA METHYLATION MAINLY CORRELATED WITH CHANGES IN GENE EXPRESSION AT MOST SITES TESTED BUT NOT AT ALL. THIS STUDY SUGGESTS THAT DNA METHYLATION CHANGES ON GENE EXPRESSION ARE NOT CLEAR-CUT AND PROVIDE A PLATFORM TO BEGIN TO UNCOVER THE RELATIONSHIP BETWEEN DNA METHYLATION AND GENE EXPRESSION, SPECIFICALLY WITHIN THE CONTEXT OF INORGANIC ARSENIC TREATMENT. 2017 6 1656 38 DOUBLE STRAND BREAKS CAN INITIATE GENE SILENCING AND SIRT1-DEPENDENT ONSET OF DNA METHYLATION IN AN EXOGENOUS PROMOTER CPG ISLAND. CHRONIC EXPOSURE TO INDUCERS OF DNA BASE OXIDATION AND SINGLE AND DOUBLE STRAND BREAKS CONTRIBUTE TO TUMORIGENESIS. IN ADDITION TO THE GENETIC CHANGES CAUSED BY THIS DNA DAMAGE, SUCH TUMORS OFTEN CONTAIN EPIGENETICALLY SILENCED GENES WITH ABERRANT PROMOTER REGION CPG ISLAND DNA HYPERMETHYLATION. WE HEREIN EXPLORE THE RELATIONSHIPS BETWEEN SUCH DNA DAMAGE AND EPIGENETIC GENE SILENCING USING AN EXPERIMENTAL MODEL IN WHICH WE INDUCE A DEFINED DOUBLE STRAND BREAK IN AN EXOGENOUS PROMOTER CONSTRUCT OF THE E-CADHERIN CPG ISLAND, WHICH IS FREQUENTLY ABERRANTLY DNA HYPERMETHYLATED IN EPITHELIAL CANCERS. FOLLOWING THE ONSET OF REPAIR OF THE BREAK, WE OBSERVE RECRUITMENT TO THE SITE OF DAMAGE OF KEY PROTEINS INVOLVED IN ESTABLISHING AND MAINTAINING TRANSCRIPTIONAL REPRESSION, NAMELY SIRT1, EZH2, DNMT1, AND DNMT3B, AND THE APPEARANCE OF THE SILENCING HISTONE MODIFICATIONS, HYPOACETYL H4K16, H3K9ME2 AND ME3, AND H3K27ME3. ALTHOUGH IN MOST CELLS SELECTED AFTER THE BREAK, DNA REPAIR OCCURS FAITHFULLY WITH PRESERVATION OF ACTIVITY OF THE PROMOTER, A SMALL PERCENTAGE OF THE PLATED CELLS DEMONSTRATE INDUCTION OF HERITABLE SILENCING. THE CHROMATIN AROUND THE BREAK SITE IN SUCH A SILENT CLONE IS ENRICHED FOR MOST OF THE ABOVE SILENT CHROMATIN PROTEINS AND HISTONE MARKS, AND THE REGION HARBORS THE APPEARANCE OF INCREASING DNA METHYLATION IN THE CPG ISLAND OF THE PROMOTER. DURING THE ACUTE BREAK, SIRT1 APPEARS TO BE REQUIRED FOR THE TRANSIENT RECRUITMENT OF DNMT3B AND SUBSEQUENT METHYLATION OF THE PROMOTER IN THE SILENT CLONES. TAKEN TOGETHER, OUR DATA SUGGEST THAT NORMAL REPAIR OF A DNA BREAK CAN OCCASIONALLY CAUSE HERITABLE SILENCING OF A CPG ISLAND-CONTAINING PROMOTER BY RECRUITMENT OF PROTEINS INVOLVED IN SILENCING. FURTHERMORE, WITH CONTRIBUTION OF THE STRESS-RELATED PROTEIN SIRT1, THE BREAK CAN LEAD TO THE ONSET OF ABERRANT CPG ISLAND DNA METHYLATION, WHICH IS FREQUENTLY ASSOCIATED WITH TIGHT GENE SILENCING IN CANCER. 2008 7 5993 36 TGFBETA PROMOTES FIBROSIS BY MYST1-DEPENDENT EPIGENETIC REGULATION OF AUTOPHAGY. ACTIVATION OF FIBROBLASTS IS ESSENTIAL FOR PHYSIOLOGICAL TISSUE REPAIR. UNCONTROLLED ACTIVATION OF FIBROBLASTS, HOWEVER, MAY LEAD TO TISSUE FIBROSIS WITH ORGAN DYSFUNCTION. ALTHOUGH SEVERAL PATHWAYS CAPABLE OF PROMOTING FIBROBLAST ACTIVATION AND TISSUE REPAIR HAVE BEEN IDENTIFIED, THEIR INTERPLAY IN THE CONTEXT OF CHRONIC FIBROTIC DISEASES REMAINS INCOMPLETELY UNDERSTOOD. HERE, WE PROVIDE EVIDENCE THAT TRANSFORMING GROWTH FACTOR-BETA (TGFBETA) ACTIVATES AUTOPHAGY BY AN EPIGENETIC MECHANISM TO AMPLIFY ITS PROFIBROTIC EFFECTS. TGFBETA INDUCES AUTOPHAGY IN FIBROTIC DISEASES BY SMAD3-DEPENDENT DOWNREGULATION OF THE H4K16 HISTONE ACETYLTRANSFERASE MYST1, WHICH REGULATES THE EXPRESSION OF CORE COMPONENTS OF THE AUTOPHAGY MACHINERY SUCH AS ATG7 AND BECLIN1. ACTIVATION OF AUTOPHAGY IN FIBROBLASTS PROMOTES COLLAGEN RELEASE AND IS BOTH, SUFFICIENT AND REQUIRED, TO INDUCE TISSUE FIBROSIS. FORCED EXPRESSION OF MYST1 ABROGATES THE STIMULATORY EFFECTS OF TGFBETA ON AUTOPHAGY AND RE-ESTABLISHES THE EPIGENETIC CONTROL OF AUTOPHAGY IN FIBROTIC CONDITIONS. INTERFERENCE WITH THE ABERRANT ACTIVATION OF AUTOPHAGY INHIBITS TGFBETA-INDUCED FIBROBLAST ACTIVATION AND AMELIORATES EXPERIMENTAL DERMAL AND PULMONARY FIBROSIS. THESE FINDINGS LINK UNCONTROLLED TGFBETA SIGNALING TO ABERRANT AUTOPHAGY AND DEREGULATED EPIGENETICS IN FIBROTIC DISEASES AND MAY CONTRIBUTE TO THE DEVELOPMENT OF THERAPEUTIC INTERVENTIONS IN FIBROTIC DISEASES. 2021 8 4702 39 NICOTINE-INDUCED OXIDATIVE STRESS CONTRIBUTES TO EMT AND STEMNESS DURING NEOPLASTIC TRANSFORMATION THROUGH EPIGENETIC MODIFICATIONS IN HUMAN KIDNEY EPITHELIAL CELLS. NICOTINE IS A COMPONENT OF CIGARETTE SMOKE AND MOUNTING EVIDENCE SUGGESTS TOXICITY AND CARCINOGENICITY OF TOBACCO SMOKE IN KIDNEY. CARCINOGENICITY OF NICOTINE ITSELF IN KIDNEY AND THE UNDERLYING MOLECULAR MECHANISMS ARE NOT WELL-UNDERSTOOD. HENCE, THE OBJECTIVE OF THIS STUDY WAS TO DETERMINE THE CARCINOGENIC EFFECTS OF CHRONIC NICOTINE EXPOSURE IN HK-2 HUMAN KIDNEY EPITHELIAL CELLS. THE EFFECTS OF NICOTINE EXPOSURE ON THE EXPRESSION OF GENES FOR CELLULAR REPROGRAMMING, REDOX STATUS, AND GROWTH SIGNALING PATHWAYS WERE ALSO EVALUATED TO UNDERSTAND THE MOLECULAR MECHANISMS. RESULTS REVEALED THAT CHRONIC EXPOSURE TO NICOTINE INDUCED GROWTH AND NEOPLASTIC TRANSFORMATION IN HK-2 CELLS. INCREASED LEVELS OF INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS), ACQUIRED STEM CELL-LIKE SPHERE FORMATION, AND EPITHELIAL-MESENCHYMAL-TRANSITION (EMT) CHANGES WERE OBSERVED IN NICOTINE EXPOSED CELLS. TREATMENT WITH ANTIOXIDANT N-ACETYL CYSTEINE (NAC) RESULTED IN ABROGATION OF EMT AND STEMNESS IN HK-2 CELLS, INDICATING THE ROLE OF NICOTINE-INDUCED ROS IN THESE MORPHOLOGICAL CHANGES. THE RESULT ALSO SUGGESTS THAT ROS CONTROLS THE STEMNESS THROUGH REGULATION OF AKT PATHWAY DURING EARLY STAGES OF CARCINOGENESIS. ADDITIONALLY, THE EXPRESSION OF EPIGENETIC REGULATORY GENES WAS ALTERED IN NICOTINE-EXPOSED CELLS AND THE CHANGES WERE REVERSED BY NAC. THE EPIGENETIC THERAPEUTICS 5-AZA-2'-DEOXYCYTIDINE AND TRICHOSTATIN A ALSO ABROGATED THE STEMNESS. THIS SUGGESTS THE NICOTINE-INDUCED OXIDATIVE STRESS CAUSED EPIGENETIC ALTERATIONS CONTRIBUTING TO STEMNESS DURING NEOPLASTIC TRANSFORMATION. TO OUR KNOWLEDGE, THIS IS THE FIRST REPORT SHOWING THE ROS-MEDIATED EPIGENETIC MODIFICATIONS AS THE UNDERLYING MECHANISM FOR CARCINOGENICITY OF NICOTINE IN HUMAN KIDNEY EPITHELIAL CELLS. THIS STUDY FURTHER SUGGESTS THE POTENTIAL OF EPIGENETIC THERAPEUTICS FOR PHARMACOLOGICAL INTERVENTION IN NICOTINE-INDUCED KIDNEY CANCER. 2019 9 1815 34 EFFECTS OF CHRONIC EXPOSURE TO ARSENIC AND ESTROGEN ON EPIGENETIC REGULATORY GENES EXPRESSION AND EPIGENETIC CODE IN HUMAN PROSTATE EPITHELIAL CELLS. CHRONIC EXPOSURES TO ARSENIC AND ESTROGEN ARE KNOWN RISK FACTORS FOR PROSTATE CANCER. THOUGH THE EVIDENCE SUGGESTS THAT EXPOSURE TO ARSENIC OR ESTROGENS CAN DISRUPT NORMAL DNA METHYLATION PATTERNS AND HISTONE MODIFICATIONS, THE MECHANISMS BY WHICH THESE CHEMICALS INDUCE EPIGENETIC CHANGES ARE NOT FULLY UNDERSTOOD. MOREOVER, THE EPIGENETIC EFFECTS OF CO-EXPOSURE TO THESE TWO CHEMICALS ARE NOT KNOWN. THEREFORE, THE OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE EFFECTS OF CHRONIC EXPOSURE TO ARSENIC AND ESTROGEN, BOTH ALONE AND IN COMBINATION, ON THE EXPRESSION OF EPIGENETIC REGULATORY GENES, THEIR CONSEQUENCES ON DNA METHYLATION, AND HISTONE MODIFICATIONS. HUMAN PROSTATE EPITHELIAL CELLS, RWPE-1, CHRONICALLY EXPOSED TO ARSENIC AND ESTROGEN ALONE AND IN COMBINATION WERE USED FOR ANALYSIS OF EPIGENETIC REGULATORY GENES EXPRESSION, GLOBAL DNA METHYLATION CHANGES, AND HISTONE MODIFICATIONS AT PROTEIN LEVEL. THE RESULT OF THIS STUDY REVEALED THAT EXPOSURE TO ARSENIC, ESTROGEN, AND THEIR COMBINATION ALTERS THE EXPRESSION OF EPIGENETIC REGULATORY GENES AND CHANGES GLOBAL DNA METHYLATION AND HISTONE MODIFICATION PATTERNS IN RWPE-1 CELLS. THESE CHANGES WERE SIGNIFICANTLY GREATER IN ARSENIC AND ESTROGEN COMBINATION TREATED GROUP THAN INDIVIDUALLY TREATED GROUP. THE FINDINGS OF THIS STUDY WILL HELP EXPLAIN THE EPIGENETIC MECHANISM OF ARSENIC- AND/OR ESTROGEN-INDUCED PROSTATE CARCINOGENESIS. 2012 10 4900 42 OXIDATIVE STRESS-INDUCED EPIGENETIC CHANGES ASSOCIATED WITH MALIGNANT TRANSFORMATION OF HUMAN KIDNEY EPITHELIAL CELLS. RENAL CELL CARCINOMA (RCC) IN HUMANS IS POSITIVELY INFLUENCED BY OXIDATIVE STRESS STATUS IN KIDNEYS. WE RECENTLY REPORTED THAT ADAPTIVE RESPONSE TO LOW LEVEL OF CHRONIC OXIDATIVE STRESS INDUCES MALIGNANT TRANSFORMATION OF IMMORTALIZED HUMAN RENAL TUBULAR EPITHELIAL CELLS. EPIGENETIC ALTERATIONS IN HUMAN RCC ARE WELL DOCUMENTED, BUT ITS ROLE IN OXIDATIVE STRESS-INDUCED MALIGNANT TRANSFORMATION OF KIDNEY CELLS IS NOT KNOWN. THEREFORE, THE OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE POTENTIAL ROLE OF EPIGENETIC CHANGES IN CHRONIC OXIDATIVE STRESS-INDUCED MALIGNANT TRANSFORMATION OF HK-2, HUMAN RENAL TUBULAR EPITHELIAL CELLS. THE RESULTS REVEALED ABERRANT EXPRESSION OF EPIGENETIC REGULATORY GENES INVOLVED IN DNA METHYLATION (DNMT1, DNMT3A AND MBD4) AND HISTONE MODIFICATIONS (HDAC1, HMT1 AND HAT1) IN HK-2 CELLS MALIGNANTLY TRANSFORMED BY CHRONIC OXIDATIVE STRESS. ADDITIONALLY, BOTH IN VITRO SOFT AGAR ASSAY AND IN VIVO NUDE MICE STUDY SHOWING DECREASED TUMORIGENIC POTENTIAL OF MALIGNANTLY TRANSFORMED HK-2 CELLS FOLLOWING TREATMENT WITH DNA DE-METHYLATING AGENT 5-AZA 2' DC FURTHER CONFIRMED THE CRUCIAL ROLE OF DNA HYPERMETHYALTION IN OXIDATIVE STRESS-INDUCED MALIGNANT TRANSFORMATION. CHANGES OBSERVED IN GLOBAL HISTONE H3 ACETYLATION (H3K9, H3K18, H3K27 AND H3K14) AND DECREASE IN PHOSPHO-H2AX (SER139) ALSO SUGGEST POTENTIAL ROLE OF HISTONE MODIFICATIONS IN INCREASED SURVIVAL AND MALIGNANT TRANSFORMATION OF HK-2 CELLS BY OXIDATIVE STRESS. IN SUMMARY, THE RESULTS OF THIS STUDY SUGGEST THAT EPIGENETIC REPROGRAMMING INDUCED BY LOW LEVELS OF OXIDATIVE STRESS ACT AS DRIVER FOR MALIGNANT TRANSFORMATION OF KIDNEY EPITHELIAL CELLS. FINDINGS OF THIS STUDY ARE HIGHLY RELEVANT IN POTENTIAL CLINICAL APPLICATION OF EPIGENETIC-BASED THERAPEUTICS FOR TREATMENTS OF KIDNEY CANCERS. 2017 11 4497 46 MORPHINE LEADS TO GLOBAL GENOME CHANGES IN H3K27ME3 LEVELS VIA A POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) SELF-REGULATORY MECHANISM IN MESCS. BACKGROUND: ENVIRONMENTALLY INDUCED EPIGENETIC CHANGES CAN LEAD TO HEALTH PROBLEMS OR DISEASE, BUT THE MECHANISMS INVOLVED REMAIN UNCLEAR. MORPHINE CAN PASS THROUGH THE PLACENTAL BARRIER LEADING TO ABNORMAL EMBRYO DEVELOPMENT. HOWEVER, THE MECHANISM BY WHICH MORPHINE CAUSES THESE EFFECTS AND HOW THEY SOMETIMES PERSIST INTO ADULTHOOD IS NOT WELL KNOWN. TO UNRAVEL THE MORPHINE-INDUCED CHROMATIN ALTERATIONS INVOLVED IN ABERRANT EMBRYO DEVELOPMENT, WE EXPLORED THE ROLE OF THE H3K27ME3/PRC2 REPRESSIVE COMPLEX IN GENE EXPRESSION AND ITS TRANSMISSION ACROSS CELLULAR GENERATIONS IN RESPONSE TO MORPHINE. RESULTS: USING MOUSE EMBRYONIC STEM CELLS AS A MODEL SYSTEM, WE FOUND THAT CHRONIC MORPHINE TREATMENT INDUCES A GLOBAL DOWNREGULATION OF THE HISTONE MODIFICATION H3K27ME3. CONVERSELY, CHIP-SEQ SHOWED A REMARKABLE INCREASE IN H3K27ME3 LEVELS AT SPECIFIC GENOMIC SITES, PARTICULARLY PROMOTERS, DISRUPTING SELECTIVE TARGET GENES RELATED TO EMBRYO DEVELOPMENT, CELL CYCLE AND METABOLISM. THROUGH A SELF-REGULATORY MECHANISM, MORPHINE DOWNREGULATED THE TRANSCRIPTION OF PRC2 COMPONENTS RESPONSIBLE FOR H3K27ME3 BY ENRICHING HIGH H3K27ME3 LEVELS AT THE PROMOTER REGION. DOWNREGULATION OF PRC2 COMPONENTS PERSISTED FOR AT LEAST 48 H (4 CELL CYCLES) FOLLOWING MORPHINE REMOVAL, THOUGH PROMOTER H3K27ME3 LEVELS RETURNED TO CONTROL LEVELS. CONCLUSIONS: MORPHINE INDUCES TARGETING OF THE PRC2 COMPLEX TO SELECTED PROMOTERS, INCLUDING THOSE OF PRC2 COMPONENTS, LEADING TO CHARACTERISTIC CHANGES IN GENE EXPRESSION AND A GLOBAL REDUCTION IN H3K27ME3. FOLLOWING MORPHINE REMOVAL, ENHANCED PROMOTER H3K27ME3 LEVELS REVERT TO NORMAL SOONER THAN GLOBAL H3K27ME3 OR PRC2 COMPONENT TRANSCRIPT LEVELS. WE SUGGEST THAT H3K27ME3 IS INVOLVED IN INITIATING MORPHINE-INDUCED CHANGES IN GENE EXPRESSION, BUT NOT IN THEIR MAINTENANCE. MODEL OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) AND H3K27ME3 ALTERATIONS INDUCED BY CHRONIC MORPHINE EXPOSURE. MORPHINE INDUCES H3K27ME3 ENRICHMENT AT PROMOTERS OF GENES ENCODING CORE MEMBERS OF THE PRC2 COMPLEX AND IS ASSOCIATED WITH THEIR TRANSCRIPTIONAL DOWNREGULATION. 2020 12 2926 41 GENERATION OF AN EPIGENETIC SIGNATURE BY CHRONIC HYPOXIA IN PROSTATE CELLS. INCREASING LEVELS OF TISSUE HYPOXIA HAVE BEEN REPORTED AS A NATURAL FEATURE OF THE AGING PROSTATE GLAND AND MAY BE A RISK FACTOR FOR THE DEVELOPMENT OF PROSTATE CANCER. IN THIS STUDY, WE HAVE USED PWR-1E BENIGN PROSTATE EPITHELIAL CELLS AND AN EQUIVALENTLY AGED HYPOXIA-ADAPTED PWR-1E SUB-LINE TO IDENTIFY PHENOTYPIC AND EPIGENETIC CONSEQUENCES OF CHRONIC HYPOXIA IN PROSTATE CELLS. WE HAVE IDENTIFIED A SIGNIFICANTLY ALTERED CELLULAR PHENOTYPE IN RESPONSE TO CHRONIC HYPOXIA AS CHARACTERIZED BY INCREASED RECEPTOR-MEDIATED APOPTOTIC RESISTANCE, THE INDUCTION OF CELLULAR SENESCENCE, INCREASED INVASION AND THE INCREASED SECRETION OF IL-1 BETA, IL6, IL8 AND TNFALPHA CYTOKINES. IN ASSOCIATION WITH THESE PHENOTYPIC CHANGES AND THE ABSENCE OF HIF-1 ALPHA PROTEIN EXPRESSION, WE HAVE DEMONSTRATED SIGNIFICANT INCREASES IN GLOBAL LEVELS OF DNA METHYLATION AND H3K9 HISTONE ACETYLATION IN THESE CELLS, CONCOMITANT WITH THE INCREASED EXPRESSION OF DNA METHYLTRANSFERASE DMNT3B AND GENE-SPECIFIC CHANGES IN DNA METHYLATION AT KEY IMPRINTING LOCI. IN CONCLUSION, WE HAVE DEMONSTRATED A GENOME-WIDE ADJUSTMENT OF DNA METHYLATION AND HISTONE ACETYLATION UNDER CHRONIC HYPOXIC CONDITIONS IN THE PROSTATE. THESE EPIGENETIC SIGNATURES MAY REPRESENT AN ADDITIONAL MECHANISM TO PROMOTE AND MAINTAIN A HYPOXIC-ADAPTED CELLULAR PHENOTYPE WITH A POTENTIAL ROLE IN TUMOUR DEVELOPMENT. 2009 13 3658 44 INDUCTION OF ABERRANT TRIMETHYLATION OF HISTONE H3 LYSINE 27 BY INFLAMMATION IN MOUSE COLONIC EPITHELIAL CELLS. A FIELD FOR CANCERIZATION (FIELD DEFECT), WHERE GENETIC AND EPIGENETIC ALTERATIONS ARE ACCUMULATED IN NORMAL-APPEARING TISSUES, IS INVOLVED IN HUMAN CARCINOGENESIS, ESPECIALLY CANCERS ASSOCIATED WITH CHRONIC INFLAMMATION. ALTHOUGH ABERRANT DNA METHYLATION IS INVOLVED IN THE FIELD DEFECT AND INDUCED BY CHRONIC INFLAMMATION, IT IS STILL UNCLEAR FOR TRIMETHYLATION OF HISTONE H3 LYSINE 27 (H3K27ME3), WHICH IS INVOLVED IN GENE REPRESSION INDEPENDENT OF DNA METHYLATION AND FUNCTIONS AS A PRE-MARK FOR ABERRANT DNA METHYLATION. IN THIS STUDY, USING A MOUSE COLITIS MODEL INDUCED BY DEXTRAN SULFATE SODIUM (DSS), WE AIMED TO CLARIFY WHETHER ABERRANT H3K27ME3 IS INDUCED BY INFLAMMATION AND INVOLVED IN A FIELD DEFECT. CHIP-ON-CHIP ANALYSIS OF COLONIC EPITHELIAL CELLS REVEALED THAT H3K27ME3 LEVELS WERE INCREASED OR DECREASED FOR 266 GENOMIC REGIONS BY AGING, AND MORE EXTENSIVELY (23 INCREASED AND 3574 DECREASED REGIONS) BY COLITIS. SUCH INCREASE OR DECREASE OF H3K27ME3 WAS INDUCED AS EARLY AS 2 WEEKS AFTER THE INITIATION OF DSS TREATMENT, AND PERSISTED AT LEAST FOR 16 WEEKS EVEN AFTER THE INFLAMMATION DISAPPEARED. SOME OF THE ABERRANT H3K27ME3 IN COLONIC EPITHELIAL CELLS WAS CARRIED OVER INTO COLON TUMORS. FURTHERMORE, H3K27ME3 ACQUIRED AT DAPK1 BY COLITIS WAS FOLLOWED BY INCREASED DNA METHYLATION, SUPPORTING ITS FUNCTION AS A PRE-MARK FOR ABERRANT DNA METHYLATION. THESE RESULTS DEMONSTRATED THAT ABERRANT H3K27ME3 CAN BE INDUCED BY EXPOSURE TO A SPECIFIC ENVIRONMENT, SUCH AS COLITIS, AND SUGGESTED THAT ABERRANT HISTONE MODIFICATION, IN ADDITION TO ABERRANT DNA METHYLATION, IS INVOLVED IN THE FORMATION OF A FIELD DEFECT. 2012 14 3738 45 INORGANIC ARSENIC-INDUCED CELLULAR TRANSFORMATION IS COUPLED WITH GENOME WIDE CHANGES IN CHROMATIN STRUCTURE, TRANSCRIPTOME AND SPLICING PATTERNS. BACKGROUND: ARSENIC (AS) EXPOSURE IS A SIGNIFICANT WORLDWIDE ENVIRONMENTAL HEALTH CONCERN. LOW DOSE, CHRONIC ARSENIC EXPOSURE HAS BEEN ASSOCIATED WITH A HIGHER THAN NORMAL RISK OF SKIN, LUNG, AND BLADDER CANCER, AS WELL AS CARDIOVASCULAR DISEASE AND DIABETES. WHILE ARSENIC-INDUCED BIOLOGICAL CHANGES PLAY A ROLE IN DISEASE PATHOLOGY, LITTLE IS KNOWN ABOUT THE DYNAMIC CELLULAR CHANGES RESULTING FROM ARSENIC EXPOSURE AND WITHDRAWAL. RESULTS: IN THESE STUDIES, WE SOUGHT TO UNDERSTAND THE MOLECULAR MECHANISMS BEHIND THE BIOLOGICAL CHANGES INDUCED BY ARSENIC EXPOSURE. A COMPREHENSIVE GLOBAL APPROACH WAS EMPLOYED TO DETERMINE GENOME-WIDE CHANGES TO CHROMATIN STRUCTURE, TRANSCRIPTOME PATTERNS AND SPLICING PATTERNS IN RESPONSE TO CHRONIC LOW DOSE ARSENIC AND ITS SUBSEQUENT WITHDRAWAL. OUR RESULTS SHOW THAT CELLS EXPOSED TO CHRONIC LOW DOSES OF SODIUM ARSENITE HAVE DISTINCT TEMPORAL AND COORDINATED CHROMATIN, GENE EXPRESSION, AND MIRNA CHANGES CONSISTENT WITH DIFFERENTIATION AND ACTIVATION OF MULTIPLE BIOCHEMICAL PATHWAYS. MOST OF THESE TEMPORAL PATTERNS IN GENE EXPRESSION ARE REVERSED WHEN ARSENIC IS WITHDRAWN. HOWEVER, SOME GENE EXPRESSION PATTERNS REMAINED ALTERED, PLAUSIBLY AS A RESULT OF AN ADAPTIVE RESPONSE BY CELLS. ADDITIONALLY, THE CORRELATION OF CHANGES TO GENE EXPRESSION AND CHROMATIN STRUCTURE SOLIDIFY THE ROLE OF CHROMATIN STRUCTURE IN GENE REGULATORY CHANGES DUE TO ARSENITE EXPOSURE. LASTLY, WE SHOW THAT ARSENITE EXPOSURE INFLUENCES GENE REGULATION BOTH AT THE INITIATION OF TRANSCRIPTION AS WELL AS AT THE LEVEL OF SPLICING. CONCLUSIONS: OUR RESULTS SHOW THAT ADAPTATION OF CELLS TO IAS-MEDIATED EMT IS COUPLED TO CHANGES IN CHROMATIN STRUCTURE EFFECTING DIFFERENTIAL TRANSCRIPTIONAL AND SPLICING PATTERNS OF GENES. THESE STUDIES PROVIDE NEW INSIGHTS INTO THE MECHANISM OF IAS-MEDIATED PATHOLOGY, WHICH INCLUDES EPIGENETIC CHROMATIN CHANGES COUPLED WITH CHANGES TO THE TRANSCRIPTOME AND SPLICING PATTERNS OF KEY GENES. 2015 15 3795 37 INTERLEUKIN-6 CONTRIBUTES TO GROWTH IN CHOLANGIOCARCINOMA CELLS BY ABERRANT PROMOTER METHYLATION AND GENE EXPRESSION. THE ASSOCIATION BETWEEN CHRONIC INFLAMMATION AND THE DEVELOPMENT AND PROGRESSION OF MALIGNANCY IS EXEMPLIFIED IN THE BILIARY TRACT WHERE PERSISTENT INFLAMMATION STRONGLY PREDISPOSES TO CHOLANGIOCARCINOMA. THE INFLAMMATORY CYTOKINE INTERLEUKIN-6 (IL-6) ENHANCES TUMOR GROWTH IN CHOLANGIOCARCINOMA BY ALTERED GENE EXPRESSION VIA AUTOCRINE MECHANISMS. IL-6 CAN REGULATE THE ACTIVITY OF DNA METHYLTRANSFERASES, AND MOREOVER, ABERRANT DNA METHYLATION CAN CONTRIBUTE TO CARCINOGENESIS. WE THEREFORE INVESTIGATED THE EFFECT OF CHRONIC EXPOSURE TO IL-6 ON METHYLATION-DEPENDENT GENE EXPRESSION AND TRANSFORMED CELL GROWTH IN HUMAN CHOLANGIOCARCINOMA. THE RELATIONSHIP BETWEEN AUTOCRINE IL-6 PATHWAYS, DNA METHYLATION, AND TRANSFORMED CELL GROWTH WAS ASSESSED USING MALIGNANT CHOLANGIOCYTES STABLY TRANSFECTED TO OVEREXPRESS IL-6. TREATMENT WITH THE DNA METHYLATION INHIBITOR 5-AZA-2'-DEOXYCYTIDINE DECREASED CELL PROLIFERATION, GROWTH IN SOFT AGAR, AND METHYLCYTOSINE CONTENT OF MALIGNANT CHOLANGIOCYTES. HOWEVER, THIS EFFECT WAS NOT OBSERVED IN IL-6-OVEREXPRESSING CELLS. IL-6 OVEREXPRESSION RESULTED IN THE ALTERED EXPRESSION AND PROMOTER METHYLATION OF SEVERAL GENES, INCLUDING THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR). EGFR PROMOTER METHYLATION WAS DECREASED AND GENE AND PROTEIN EXPRESSION WAS INCREASED BY IL-6. THUS, EPIGENETIC REGULATION OF GENE EXPRESSION BY IL-6 CAN CONTRIBUTE TO TUMOR PROGRESSION BY ALTERING PROMOTER METHYLATION AND GENE EXPRESSION OF GROWTH-REGULATORY PATHWAYS, SUCH AS THOSE INVOLVING EGFR. MOREOVER, ENHANCED IL-6 EXPRESSION MAY DECREASE THE SENSITIVITY OF TUMOR CELLS TO THERAPEUTIC TREATMENTS USING METHYLATION INHIBITORS. THESE OBSERVATIONS HAVE IMPORTANT IMPLICATIONS FOR CANCER TREATMENT AND PROVIDE A MECHANISM BY WHICH PERSISTENT CYTOKINE STIMULATION CAN PROMOTE TUMOR GROWTH. 2006 16 4004 36 LOSS OF THE POLYCOMB MARK FROM BIVALENT PROMOTERS LEADS TO ACTIVATION OF CANCER-PROMOTING GENES IN COLORECTAL TUMORS. IN COLON TUMORS, THE TRANSCRIPTION OF MANY GENES BECOMES DEREGULATED BY POORLY DEFINED EPIGENETIC MECHANISMS THAT HAVE BEEN STUDIED MAINLY IN ESTABLISHED CELL LINES. IN THIS STUDY, WE USED FROZEN HUMAN COLON TISSUES TO ANALYZE PATTERNS OF HISTONE MODIFICATION AND DNA CYTOSINE METHYLATION IN CANCER AND MATCHED NORMAL MUCOSA SPECIMENS. DNA METHYLATION IS STRONGLY TARGETED TO BIVALENT H3K4ME3- AND H3K27ME3-ASSOCIATED PROMOTERS, WHICH LOSE BOTH HISTONE MARKS AND ACQUIRE DNA METHYLATION. HOWEVER, WE FOUND THAT LOSS OF THE POLYCOMB MARK H3K27ME3 FROM BIVALENT PROMOTERS WAS ACCOMPANIED OFTEN BY ACTIVATION OF GENES ASSOCIATED WITH CANCER PROGRESSION, INCLUDING NUMEROUS STEM CELL REGULATORS, ONCOGENES, AND PROLIFERATION-ASSOCIATED GENES. INDEED, WE FOUND MANY OF THESE SAME GENES WERE ALSO ACTIVATED IN PATIENTS WITH ULCERATIVE COLITIS WHERE CHRONIC INFLAMMATION PREDISPOSES THEM TO COLON CANCER. BASED ON OUR FINDINGS, WE PROPOSE THAT A LOSS OF POLYCOMB REPRESSION AT BIVALENT GENES COMBINED WITH AN ENSUING SELECTION FOR TUMOR-DRIVING EVENTS PLAYS A MAJOR ROLE IN CANCER PROGRESSION. 2014 17 3042 39 GENOME-WIDE ALTERATION OF HISTONE METHYLATION PROFILES ASSOCIATED WITH COGNITIVE CHANGES IN RESPONSE TO DEVELOPMENTAL ARSENIC EXPOSURE IN MICE. INORGANIC ARSENIC IS A XENOBIOTIC ENTERING THE BODY PRIMARILY THROUGH CONTAMINATED DRINKING WATER AND FOOD. THERE ARE DEFINED MECHANISMS THAT DESCRIBE ARSENIC'S ASSOCIATION WITH INCREASED CANCER INCIDENCE, HOWEVER MECHANISMS EXPLAINING ARSENIC EXPOSURE AND NEURODEVELOPMENTAL OR AGING DISORDERS ARE POORLY DEFINED. IN RECENT YEARS, ARSENIC EFFECTS ON EPIGENOME HAVE BECOME A PARTICULAR FOCUS. WE HYPOTHESIZE THAT HUMAN RELEVANT ARSENIC EXPOSURE DURING PARTICULAR DEVELOPMENTAL WINDOWS, OR LONG-TERM EXPOSURE LATER IN LIFE INDUCE PATHOPHYSIOLOGICAL NEURAL CHANGES THROUGH EPIGENOMIC ALTERATIONS, IN PARTICULAR HISTONE METHYLATION PROFILE, MANIFESTING AS COGNITIVE DECLINE. C57BL/6 WILD-TYPE MICE WERE CONTINUALLY EXPOSED TO SODIUM ARSENITE (100 MICROG/L) IN DRINKING WATER PRIOR TO MATING THROUGH WEANING OF THE EXPERIMENTAL PROGENY. A SECOND COHORT OF AGED APP/PS MICE WERE CHRONICALLY EXPOSED TO THE SAME LEVEL OF ARSENIC. COGNITIVE TESTING, HISTOLOGICAL EXAMINATION OF BRAINS AND GENOME-WIDE METHYLATION LEVELS OF H3K4ME3 AND H3K27ME3 EXAMINED AFTER CHIP-SEQ WERE USED TO DETERMINE THE EFFECTS OF ARSENIC EXPOSURE. DEVELOPMENTAL ARSENIC EXPOSURE CAUSED SIGNIFICANTLY DIMINISHED COGNITION IN WILD-TYPE MICE. THE ANALYSIS OF CHIP-SEQ DATA AND EXPERIMENTS WITH MOUSE EMBRYONIC STEM CELLS DEMONSTRATED THAT EPIGENETIC CHANGES INDUCED BY ARSENIC EXPOSURE TRANSLATED INTO GENE EXPRESSION ALTERATIONS ASSOCIATED WITH NEURONAL DEVELOPMENT AND NEUROLOGICAL DISEASE. INCREASED HIPPOCAMPAL AMYLOID PLAQUES LEVELS OF APP/PS MICE AND COGNITIVE DECLINE PROVIDED EVIDENCE THAT ARSENIC EXPOSURE AGGRAVATED AN EXISTING ALZHEIMER'S DISEASE-LIKE PHENOTYPE. WE SHOW DEVELOPMENTAL ARSENIC EXPOSURE SIGNIFICANTLY IMPACTS HISTONE MODIFICATIONS IN BRAIN WHICH REMAIN PRESENT INTO ADULTHOOD AND PROVIDE A POTENTIAL MECHANISM BY WHICH DEVELOPMENTAL ARSENIC EXPOSURE INFLUENCES COGNITIVE FUNCTIONS. WE ALSO SHOW THAT HUMAN RELEVANT, CHRONIC ARSENIC EXPOSURE HAS DELETERIOUS EFFECTS ON ADULT APP/PS MICE AND EXACERBATES EXISTING ALZHEIMER'S DISEASE-LIKE SYMPTOMS. THE RESULTS DEMONSTRATE HOW DEVELOPMENTAL ARSENIC EXPOSURE IMPACTS THE BRAIN EPIGENOME, LEADING TO ALTERED GENE EXPRESSION LATER IN LIFE. 2022 18 4215 41 METHYL DEFICIENCY, ALTERATIONS IN GLOBAL HISTONE MODIFICATIONS, AND CARCINOGENESIS. THE METHYL-DEFICIENT MODEL OF ENDOGENOUS HEPATOCARCINOGENESIS IN RODENTS IS UNIQUE IN THAT DIETARY OMISSION RATHER THAN THE ADDITION OF CHEMICAL CARCINOGENS LEADS TO TUMOR FORMATION. THUS, THE BIOCHEMICAL AND MOLECULAR EVENTS PREDISPOSING TO CANCER IN THIS MODEL RESULT FROM CHRONIC METABOLIC STRESS AND PROVIDE AN IDEAL MODEL SYSTEM TO STUDY PROGRESSIVE ALTERATIONS THAT OCCUR DURING CARCINOGENESIS. MOREOVER, EPIGENETIC ALTERATIONS IMPOSED BY THIS DIET ARE BELIEVED TO BE 1 OF THE MAIN MECHANISMS RESPONSIBLE FOR MALIGNANT TRANSFORMATION OF RAT LIVER CELLS. IN THIS STUDY WE EXAMINED THE CHANGES IN GLOBAL HISTONE MODIFICATION PATTERNS IN LIVER DURING HEPATOCARCINOGENESIS INDUCED BY METHYL DEFICIENCY. FEEDING ANIMALS THE METHYL-DEFICIENT DIET (MDD) LED TO PROGRESSIVE LOSS OF HISTONE H4 LYSINE 20 TRIMETHYLATION (H4K20ME3), H3 LYSINE 9 TRIMETHYLATION (H3K9ME3), AND HISTONE H3 LYSINE 9 (H3K9AC) AND HISTONE H4 LYSINE 16 (H4K16AC) ACETYLATION. A CONSIDERABLE DECREASE OF H4K20ME3 AND H3K9AC WAS ALSO DETECTED IN LIVER TUMORS INDUCED BY MDD. IN CONTRAST, LIVER TUMORS DISPLAYED AN INCREASE IN H3K9ME3 AND H4K16AC. TO DETERMINE THE POSSIBLE MECHANISM OF ALTERATIONS OF HISTONE MODIFICATIONS, WE ANALYZED THE EXPRESSION OF HISTONE-MODIFYING ENZYMES IN LIVER DURING HEPATOCARCINOGENESIS. THE EXPRESSION OF SUV4-20H2 AND RIZ1 HISTONE METHYLTRANSFERASES (HMTS) STEADILY DECREASED ALONG WITH THE DEVELOPMENT OF LIVER TUMORS AND REACHED ITS LOWEST LEVEL IN TUMOR TISSUE, WHEREAS THE EXPRESSION OF SUV39-H1 HMT AND HISTONE ACETYLTRANSFERASE 1 (HAT1) SUBSTANTIALLY INCREASED IN TUMORS. THESE RESULTS ILLUSTRATE THE COMPLEXITY AND IMPORTANCE OF HISTONE MODIFICATION CHANGES IN THE ETIOLOGY OF HEPATOCARCINOGENESIS INDUCED BY MDD. 2007 19 902 41 CHRONIC EXPOSURE TO ARSENIC, ESTROGEN, AND THEIR COMBINATION CAUSES INCREASED GROWTH AND TRANSFORMATION IN HUMAN PROSTATE EPITHELIAL CELLS POTENTIALLY BY HYPERMETHYLATION-MEDIATED SILENCING OF MLH1. BACKGROUND: CHRONIC EXPOSURE TO ARSENIC AND ESTROGEN IS ASSOCIATED WITH RISK OF PROSTATE CANCER, BUT THEIR MECHANISM IS NOT FULLY UNDERSTOOD. ADDITIONALLY, THE CARCINOGENIC EFFECTS OF THEIR CO-EXPOSURE ARE NOT KNOWN. THEREFORE, THE OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE EFFECTS OF CHRONIC EXPOSURE TO ARSENIC, ESTROGEN, AND THEIR COMBINATION, ON CELL GROWTH AND TRANSFORMATION, AND IDENTIFY THE MECHANISM BEHIND THESE EFFECTS. METHODS: RWPE-1 HUMAN PROSTATE EPITHELIAL CELLS WERE CHRONICALLY EXPOSED TO ARSENIC AND ESTROGEN ALONE AND IN COMBINATION. CELL GROWTH WAS MEASURED BY CELL COUNT AND CELL CYCLE, WHEREAS CELL TRANSFORMATION WAS EVALUATED BY COLONY FORMATION ASSAY. GENE EXPRESSION WAS MEASURED BY QUANTITATIVE REAL-TIME PCR AND CONFIRMED AT PROTEIN LEVEL BY WESTERN BLOT ANALYSIS. MLH1 PROMOTER METHYLATION WAS DETERMINED BY PYROSEQUENCING METHOD. RESULTS: EXPOSURE TO ARSENIC, ESTROGEN, AND THEIR COMBINATIONS INCREASES CELL GROWTH AND TRANSFORMATION IN RWPE-1 CELLS. INCREASED EXPRESSION OF CYCLIN D1 AND BCL2, WHEREAS DECREASED EXPRESSION OF MISMATCH REPAIR GENES MSH4, MSH6, AND MLH1 WAS ALSO OBSERVED. HYPERMETHYLATION OF MLH1 PROMOTER FURTHER SUGGESTED THE EPIGENETIC INACTIVATION OF MLH1 EXPRESSION IN ARSENIC AND ESTROGEN TREATED CELLS. ARSENIC AND ESTROGEN COMBINATION CAUSED GREATER CHANGES THAN THEIR INDIVIDUAL TREATMENTS. CONCLUSIONS: FINDINGS OF THIS STUDY FOR THE FIRST TIME SUGGEST THAT ARSENIC AND ESTROGEN EXPOSURES CAUSE INCREASED CELL GROWTH AND SURVIVAL POTENTIALLY THROUGH EPIGENETIC INACTIVATION OF MLH1 RESULTING IN DECREASED MLH1-MEDIATED APOPTOTIC RESPONSE, AND CONSEQUENTLY INCREASED CELLULAR TRANSFORMATION. 2013 20 3508 33 IDENTIFYING A PANEL OF GENES/PROTEINS/MIRNAS MODULATED BY ARSENICALS IN BLADDER, PROSTATE, KIDNEY CANCERS. ARSENIC AND ARSENIC-DERIVATIVE COMPOUNDS, NAMED AS ARSENICALS, REPRESENT A WORLDWIDE PROBLEM FOR THEIR EFFECT ON THE HUMAN HEALTH AND, IN PARTICULAR, FOR THEIR CAPABILITY TO INCREASE THE RISK OF DEVELOPING CANCER SUCH AS KIDNEY, BLADDER AND PROSTATE CANCER. THE MAIN SOURCE OF ARSENICAL EXPOSURE IS DRINKING WATER. NOWADAYS, IT IS WELL KNOWN THAT THE CHRONIC EXPOSURE TO ARSENICALS LEADS TO A SERIES OF EPIGENETIC ALTERATIONS THAT HAVE A ROLE IN ARSENIC-INDUCED EFFECTS ON HUMAN HEALTH INCLUDING CANCER. BASED ON THESE OBSERVATIONS, THE AIM OF OUR STUDY WAS TO SELECT BY NETWORK ANALYSIS THE GENES/PROTEINS/MIRNAS IMPLICATED IN KIDNEY, BLADDER AND PROSTATE CANCER DEVELOPMENT UPON ARSENICAL EXPOSURE. FROM THIS ANALYSIS WE IDENTIFIED: (I) THE NODES LINKING THE THREE MOLECULAR NETWORKS SPECIFIC FOR KIDNEY, BLADDER AND PROSTATE CANCER; (II) THE RELATIVE HUB NODES (RXRA, MAP3K7, NR3C1, PABPC1, NDRG1, RELA AND CTNNB1) THAT LINK THE THREE CANCER NETWORKS; (III) THE MIRNAS ABLE TO TARGET THESE HUB NODES. IN CONCLUSION, WE HIGHLIGHTED A PANEL OF POTENTIAL MOLECULES RELATED TO THE MOLECULAR MECHANISMS OF ARSENICAL-INDUCED CANCEROGENESIS AND SUGGEST THEIR UTILITY AS BIOMARKERS OR THERAPEUTIC TARGETS. 2018